Bouraguba M, Schmitt AM, Suseela YV, Vileno B, Melin F, Glattard E, Orvain C, Lebrun V, Raibaut L, Ilbert M, Bechinger B, Hellwig P, Gaiddon C, Sour A, Faller P

Metallomics. 2024 04 13;:

The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.

Riegel G, Orvain C, Recberlik S, Spaety ME, Poschet G, Venkatasamy A, Yamamoto M, Nomura S, Tsukamoto T, Masson M, Gross I, Le Lagadec R, Mellitzer G, Gaiddon C

Cancer Lett. 2024 01 28;:216671

Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation.

Kwan K, Castro-Sandoval O, Ma B, Martelino D, Saffari A, Liu XL, Orvain C, Mellitzer G, Gaiddon C, Storr T

J Inorg Biochem. 2023 11 22;251:112433

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Mourtada J, Lony C, Nicol A, De Azevedo J, Bour C, Macabre C, Roncarati P, Ledrappier S, Schultz P, Borel C, Burgy M, Wasylyk B, Mellitzer G, Herfs M, Gaiddon C, Jung AC

Front Immunol. 2023 10 25;14:1264093

A Novel Near-IR Absorbing Ruthenium(II) Complex as Photosensitizer for Photodynamic Therapy and its Cetuximab Bioconjugates.

Martínez-Alonso M, Gandioso A, Thibaudeau C, Qin X, Arnoux P, Demeubayeva N, Guérineau V, Frochot C, Jung AC, Gaiddon C, Gasser G

Chembiochem. 2023 04 5;:e202300203

Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.

Miller JJ, Kwan K, Blanchet A, Orvain C, Mellitzer G, Smith J, Lento C, Nouchikian L, Omoregbee-Leichnitz S, Sabatou M, Wilson D, Gaiddon C, Storr T

J Inorg Biochem. 2023 02 21;242:112164

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Gastric Cancer. 2022 12 19;:

Inhibition of p53 protein aggregation as a cancer treatment strategy.

Kwan K, Castro-Sandoval O, Gaiddon C, Storr T

Curr Opin Chem Biol. 2022 11 24;72:102230

Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer.

Hou L, Hou Y, Liang Y, Chen B, Zhang X, Wang Y, Zhou K, Zhong T, Long B, Pang W, Wang L, Han X, Li L, Xu C, Gross I, Gaiddon C, Fu W, Yao H, Meng X

Commun Biol. 2022 11 14;5(1):1248

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?

Badie A, Gaiddon C, Mellitzer G

Cancers (Basel). 2022 11 7;14(21):

Sarcopenia remaining after intensive nutritional feeding support could be a criterion for the selection of patients for surgery for oesogastric junction adenocarcinoma.

de Mathelin P, Manfredelli S, Delhorme JB, Venkatasamy A, Rohr S, Brigand C, Gaiddon C, Romain B

Eur J Surg Oncol. 2022 11 5;:

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.

De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC

Cells. 2022 09 14;11(18):

Targeting of the intracellular redox balance by metal complexes towards anticancer therapy.

Murillo MI, Gaiddon C, Le Lagadec R

Front Chem. 2022 08 11;10:967337

A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.

Miller JJ, Kwan K, Gaiddon C, Storr T

J Biol Inorg Chem. 2022 Apr 30;:

High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression.

Poirson J, Suarez IP, Straub ML, Cousido-Siah A, Peixoto P, Hervouet E, Foster A, Mitschler A, Mukobo N, Chebaro Y, Garcin D, Recberlik S, Gaiddon C, Altschuh D, Nominé Y, Podjarny A, Trave G, Masson M

J Virol. 2022 Apr 27;:e0187521

Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?

Jung AC, Moinard-Butot F, Thibaudeau C, Gasser G, Gaiddon C

Pharmaceutics. 2021 Oct 26;13(11):

Ultrasound and Transcriptomics Identify a Differential Impact of Cisplatin and Histone Deacetylation on Tumor Structure and Microenvironment in a Patient-Derived In Vivo Model of Gastric Cancer.

Venkatasamy A, Guerin E, Blanchet A, Orvain C, Devignot V, Jung M, Jung AC, Chenard MP, Romain B, Gaiddon C, Mellitzer G

Pharmaceutics. 2021 Sep 16;13(9):

Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer.

Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, Delhorme JB, Venkatasamy A, Jung AC, Pfeffer M

Molecules. 2021 Sep 4;26(17):

Gold(III) to Ruthenium(III) Metal Exchange in Dithiocarbamato Complexes Tunes Their Biological Mode of Action for Cytotoxicity in Cancer Cells.

Dalla Pozza M, Orvain C, Brustolin L, Pettenuzzo N, Nardon C, Gaiddon C, Fregona D

Molecules. 2021 Jul 3;26(13):

Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.

Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C

Cancers (Basel). 2021 Feb 22;13(4):

Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System.

Mueller CG, Gaiddon C, Venkatasamy A

Front Immunol. 2021 ;12:716860

The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms.

Beck M, Baranger M, Moufok-Sadoun A, Bersuder E, Hinkel I, Mellitzer G, Martin E, Marisa L, Duluc I, de Reynies A, Gaiddon C, Freund JN, Gross I

Oncogene. 2020 Nov 13;:

A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.

Miller JJ, Gaiddon C, Storr T

Chem Soc Rev. 2020 Sep 1;:

How to Prevent Sarcopenia Occurrence during Neoadjuvant Chemotherapy for Oesogastric Adenocarcinoma?

Voisinet M, Venkatasamy A, Alratrout H, Delhorme JB, Brigand C, Rohr S, Gaiddon C, Romain B

Nutr Cancer. 2020 May 25;:1-7

Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells.

Solís-Ruiz JA, Barthe A, Riegel G, Saavedra-Díaz RO, Gaiddon C, Le Lagadec R

J. Inorg. Biochem.. 2020 Mar 28;208:111080

Bifunctional ligand design for modulating mutant p53 aggregation in cancer.

Miller JJ, Blanchet A, Orvain C, Nouchikian L, Reviriot Y, Clarke RM, Martelino D, Wilson D, Gaiddon C, Storr T

Chem Sci. 2019 Dec 14;10(46):10802-10814

HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.

Spaety ME, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C, Yanagihara K, Okamoto K, Jung AC, Mellitzer G, Pfeffer S, Gaiddon C

Cancers (Basel). 2019 Nov 7;11(11):

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC.

Coliat P, Ramolu L, Jégu J, Gaiddon C, Jung AC, Pencreach E

Cancers (Basel). 2019 Oct 21;11(10):

Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway.

Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, Huang X, Hou Y, Zhu D, Zou H, Gu Y, Weng X, Wang Y, Li Y, Wu T, Yao M, Gross I, Gaiddon C, Luo M, Wang J, Meng X

Oncogene. 2019 Oct 9;:

Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on -Driven Oncogenic Addiction.

Job S, Reyniès A, Heller B, Weiss A, Guérin E, Macabre C, Ledrappier S, Bour C, Wasylyk C, Etienne-Selloum N, Brino L, Gaiddon C, Wasylyk B, Jung AC

Cancers (Basel). 2019 Jun 8;11(6):

Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation.

Santoro A, Vileno B, Palacios Ò, Peris-Díaz MD, Riegel G, Gaiddon C, Krężel A, Faller P

Metallomics. 2019 Apr 23;:

From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents.

Lam NYS, Truong D, Burmeister H, Babak MV, Holtkamp HU, Movassaghi S, Ayine-Tora DM, Zafar A, Kubanik M, Oehninger L, Söhnel T, Reynisson J, Jamieson SMF, Gaiddon C, Ott I, Hartinger CG

Inorg Chem. 2018 Nov 8;:

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Camacho RC, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C

Cancer Lett.. 2018 Oct 16;:

Use of a case-mix approach to study the trends in the incidence of second primary cancers.

Gass B, Marrer E, Bara S, Ligier K, Molinié F, Colonna M, Daubisse-Marliac L, Trétarre B, Lapôtre-Ledoux B, Woronoff AS, Guizard AV, Bouvier V, Troussard X, Gaiddon C, Klein D, Velten M, Jégu J

Ann Epidemiol. 2018 May;28(5):322-327

The Champagne sign.

Minault Q, Gaiddon C, Veillon F, Venkatasamy A

Abdom Radiol (NY). 2018 Mar 10;:

Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action.

Babak MV, Pfaffeneder-Kmen M, Meier-Menches SM, Legina MS, Theiner S, Licona C, Orvain C, Hejl M, Hanif M, Jakupec MA, Keppler BK, Gaiddon C, Hartinger CG

Inorg Chem. 2018 Mar 5;57(5):2851-2864

Holographic Traction Force Microscopy.

Makarchuk S, Beyer N, Gaiddon C, Grange W, Hébraud P

Sci Rep. 2018 Feb 14;8(1):3038

Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma?

Manfredelli S, Delhorme JB, Venkatasamy A, Gaiddon C, Brigand C, Rohr S, Romain B

Ann. Surg. Oncol.. 2017 Jun;:

Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies.

Chow MJ, Alfiean M, Pastorin G, Gaiddon C, Ang WH

Chem Sci. 2017 May 1;8(5):3641-3649

The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton.

Platet N, Hinkel I, Richert L, Murdamoothoo D, Moufok-Sadoun A, Vanier M, Lavalle P, Gaiddon C, Vautier D, Freund JN, Gross I

Cancer Lett.. 2017 Feb;386:57-64

A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Licona C, Spaety ME, Capuozzo A, Ali M, Santamaria R, Armant O, Delalande F, Van Dorsselaer A, Cianferani S, Spencer J, Pfeffer M, Mellitzer G, Gaiddon C

Oncotarget. 2017 Jan;8(2):2568-2584

Monomeric Ti(iv)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities.

Khalil G, Orvain C, Fang L, Barloy L, Chaumont A, Gaiddon C, Henry M, Kyritsakas N, Mobian P

Dalton Trans. 2016 Nov;45(47):19072-19085

Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells.

Rico Bautista H, Saavedra Díaz RO, Shen LQ, Orvain C, Gaiddon C, Le Lagadec R, Ryabov AD

J. Inorg. Biochem.. 2016 Oct;163:28-38

Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.

Chow MJ, Babak MV, Wong DY, Pastorin G, Gaiddon C, Ang WH

Mol. Pharm.. 2016 Jul;13(7):2543-54

Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance.

Chow MJ, Licona C, Pastorin G, Mellitzer G, Ang WH, Gaiddon C

Chem Sci. 2016 Jul 1;7(7):4117-4124

Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63.

von Grabowiecki Y, Abreu P, Blanchard O, Palamiuc L, Benosman S, Mériaux S, Devignot V, Gross I, Mellitzer G, Gonzalez de Aguilar JL, Gaiddon C

Elife. 2016 Feb;5:

Gold-phosphine-porphyrin as potential metal-based theranostics.

Tasan S, Licona C, Doulain PE, Michelin C, Gros CP, Le Gendre P, Harvey PD, Paul C, Gaiddon C, Bodio E

J Biol Inorg Chem. 2015 Jan;20(1):143-54

Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy.

von Grabowiecki Y, Licona C, Palamiuc L, Abreu P, Vidimar V, Coowar D, Mellitzer G, Gaiddon C

J Pharmacol Exp Ther. 2015 Jan;352(1):23-32

Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.

Chow MJ, Licona C, Yuan Qiang Wong D, Pastorin G, Gaiddon C, Ang WH

J Med Chem. 2014 Jul 24;57(14):6043-59

Design of Porphyrin-dota-Like Scaffolds as All-in-One Multimodal Heterometallic Complexes for Medical Imaging.

Eggenspiller A, Michelin C, Desbois N, Richard P, Barbe JM, Denat F, Licona C, Gaiddon C, Sayeh A, Choquet P, Gros CP

Eur J Org Chem. 2013 Oct;2013(29):6629-43.

Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes.

Boff B, Gaiddon C, Pfeffer M

Inorg Chem. 2013 Mar 4;52(5):2705-15

Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity.

Vidimar V, Meng X, Klajner M, Licona C, Fetzer L, Harlepp S, Hebraud P, Sidhoum M, Sirlin C, Loeffler JP, Mellitzer G, Sava G, Pfeffer M, Gaiddon C

Biochem Pharmacol. 2012 Dec 1;84(11):1428-36

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Desaubry L

J Med Chem. 2012 Nov 26;55(22):10064-73

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G

J Inorg Biochem. 2012 Jan;106(1):90-9

Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons.

Benosman S, Meng X, Von Grabowiecki Y, Palamiuc L, Hritcu L, Gross I, Mellitzer G, Taya Y, Loeffler JP, Gaiddon C

J Biol Chem. 2011 Dec 16;286(50):43013-25

Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.

Fetzer L, Boff B, Ali M, Xiangjun M, Collin JP, Sirlin C, Gaiddon C, Pfeffer M

Dalton Trans. 2011 Sep 21;40(35):8869-78

Novel flavaglines displaying improved cytotoxicity.

Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Desaubry L

J Med Chem. 2011 Jan 13;54(1):411-5

DNA binding to an anticancer organo-ruthenium complex.

Klajner M, Hebraud P, Sirlin C, Gaiddon C, Harlepp S

J Phys Chem B. 2010 Nov 11;114(44):14041-7.

Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.

Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y, Okamoto K

Cancer Sci. 2009 Jul;100(7):1291-9

Evaluation of the ability of an organic derivative of ruthenium(II) to reinforce the cytotoxicity of fast neutron against malignant cells in culture

Leyva L, Malek F, Benzina S, Denis JM, Gueulette J, Dufour P, Gaiddon C, Loeffler JP, Sirlin C, Pfeffer M, Bischoff P

Lett Drug Des Discov. 2008 Jan;5(1):1-6

Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms.

Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP

J Pharmacol Exp Ther. 2005 Dec;315(3):1403-11

Tissue specificity and regulation of the N-terminal diversity of reticulon 3.

Di Scala F, Dupuis L, Gaiddon C, De Tapia M, Jokic N, Gonzalez de Aguilar JL, Raul JS, Ludes B, Loeffler JP

Biochem J. 2005 Jan 1;385(Pt 1):125-34.

Fiche personne Projets Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques